Advertisement

Topics

Leerink Swann Reiterates Outperform Rating for Bristol-Myers Squibb Co

21:54 EDT 2 Apr 2017 | Topix

's stock had its "outperform" rating reaffirmed by Leerink Swann in a note issued to investors on Monday. They presently have a $62.00 target price on the biopharmaceutical company's stock.

Original Article: Leerink Swann Reiterates Outperform Rating for Bristol-Myers Squibb Co

NEXT ARTICLE

More From BioPortfolio on "Leerink Swann Reiterates Outperform Rating for Bristol-Myers Squibb Co"

Quick Search
Advertisement
 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...